리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 09월
페이지 정보:영문 168 Pages
라이선스 & 가격 (부가세 별도)
한글목차
내분비 검사 세계 시장은 2030년까지 169억 달러에 달할 것으로 전망
2023년에 120억 달러로 추정되는 내분비 검사 세계 시장은 2023년부터 2030년까지 연평균 5.0% 성장하여 2030년에는 169억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 탠덤 질량 분석 기술은 CAGR 6.2%를 기록하여 분석 기간 종료 시점에 53억 달러에 도달할 것으로 예상됩니다. 면역 분석 기술 분야의 성장률은 분석 기간 동안 CAGR 5.0%로 추정됩니다.
미국 시장은 32억 달러로 추정, 중국은 CAGR 7.7%로 성장 전망
미국 내분비 검사 시장은 2023년 32억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2023-2030년의 분석 기간 동안 7.7%의 연평균 복합 성장률(CAGR)을 기록하여 2030년에는 38억 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 2.5%와 4.7%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 2.9%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.
세계 내분비 검사 시장 - 주요 동향 및 촉진요인 요약
내분비 검사는 건강 관리와 질병 관리에 어떤 혁명을 가져올 것인가?
내분비 검사는 신진대사, 성장, 생식 및 전반적인 건강 조절에 중요한 역할을 하는 체내 호르몬 시스템의 기능에 대한 중요한 통찰력을 제공함으로써 건강 관리 및 질병 관리에 혁명을 일으키고 있습니다. 이 검사는 혈액, 소변, 타액 샘플을 분석하여 호르몬 수치를 측정하여 당뇨병, 갑상선 질환, 부신 기능 부전, 생식 건강 문제 등 다양한 내분비 질환을 진단, 모니터링 및 관리하는 데 도움을 줄 수 있습니다. 호르몬 불균형을 정확하게 감지하고 모니터링하는 것은 효과적인 치료를 위해 필수적입니다. 검사 기술의 발전으로 내분비 검사는 더 정확하고, 더 쉽게 이용할 수 있고, 더 종합적인 검사를 할 수 있게 되었으며, 의료 서비스 제공업체는 더 일찍 상태를 진단하고, 더 효과적으로 치료를 조정하고, 더 정확하게 경과를 관찰할 수 있게 되었습니다. 내분비 시스템에 대한 이해가 깊어지고 비만, 심혈관 질환, 골다공증과 같은 만성 질환과의 연관성이 밝혀짐에 따라 내분비 검사는 예방 및 개인화된 의료의 핵심으로 점점 더 많은 관심을 받고 있습니다.
내분비 검사 기능을 향상시키는 혁신이란?
내분비 검사의 혁신은 진단 기술, 자동화 및 개인 맞춤형 의료의 발전을 통해 그 기능을 강화하고 있습니다. 가장 중요한 발전 중 하나는 면역 분석 및 질량 분석과 같은 고감도 및 특이적 분석의 도입입니다. 이러한 고급 분석법은 위양성 및 위음성의 가능성을 줄이고 보다 신뢰할 수 있는 진단 정보를 제공합니다. 내분비 검사실의 자동화 또한 중요한 혁신으로, 최소한의 인력 개입으로 샘플의 높은 처리량을 처리할 수 있게 해줍니다. 이는 검사 프로세스의 속도를 높일 뿐만 아니라 인적 오류의 가능성을 줄여 일관되고 정확한 결과를 보장합니다. 또한, 내분비 검사와 개인 맞춤형 의료 접근법의 통합은 호르몬 관련 질환을 관리하는 방식을 변화시키고 있습니다. 호르몬 수치 데이터를 유전적, 생활습관적, 환경적 요인과 결합하여 의료진은 각 환자의 고유한 요구에 맞는 맞춤형 치료 계획을 수립하여 결과를 개선하고 합병증 위험을 줄일 수 있습니다. 또한, 코티솔이나 갑상선자극호르몬(TSH)과 같은 특정 호르몬에 대한 가정용 검사 키트의 개발로 내분비 검사가 일반인에게 더욱 친숙해져 개인이 편리하고 자주 호르몬 수치를 모니터링할 수 있게 되었습니다. 이러한 기술 혁신은 내분비 검사를 보다 정확하고 효율적이며 환자 중심적으로 만들어 내분비 질환의 진단과 관리를 개선하는 데 기여하고 있습니다.
내분비 검사는 질병 관리와 환자 결과에 어떤 영향을 미칩니 까?
내분비 검사는 호르몬 관련 질환의 조기 진단, 표적 치료 및 지속적인 모니터링을 가능하게 함으로써 질병 관리와 환자 예후에 큰 영향을 미칩니다. 갑상선 기능 항진증, 당뇨병, 부신 기능 저하증과 같은 내분비 질환을 조기에 발견하면 적시에 개입할 수 있어 질환의 진행을 막고 심각한 합병증 위험을 줄일 수 있습니다. 예를 들어, 내분비 검사를 통해 갑상선 기능 장애를 조기에 발견하면 치료되지 않은 갑상선 질환으로 인해 발생할 수 있는 심장병, 정신 건강 문제 등의 합병증을 예방할 수 있습니다. 당뇨병과 같은 만성질환의 치료에서 정기적인 내분비 검사는 혈당 수치 모니터링에 필수적이며, 필요에 따라 치료 계획을 조정하여 최적의 혈당 조절을 유지하고 신경장애, 심혈관 질환 등의 합병증을 예방할 수 있습니다. 또한, 호르몬 수치를 정확하게 측정하고 모니터링할 수 있게 됨에 따라 의료진은 치료를 미세 조정할 수 있고, 약물의 용량을 정확하게 조절하고 개인의 호르몬 프로파일에 맞는 치료를 할 수 있습니다. 이러한 개별화된 접근 방식은 치료 효과를 향상시킬 뿐만 아니라 환자의 순응도와 만족도를 높일 수 있습니다. 내분비 검사는 내분비 질환의 관리를 안내하는 중요한 정보를 제공함으로써 환자의 결과와 삶의 질을 개선하는 데 중요한 역할을 합니다.
내분비 검사 시장의 성장을 가속하는 추세는?
내분비 질환의 유병률 증가, 진단 기술의 발전, 예방 의료에 대한 관심 증가 등 여러 가지 트렌드가 내분비 검사 시장의 성장을 가속하고 있습니다. 당뇨병, 갑상선 질환, 대사증후군과 같은 질병이 전 세계적으로 증가하고 있으며, 이러한 질병은 지속적인 모니터링과 관리가 필요하기 때문에 정확하고 종합적인 내분비 검사에 대한 수요가 증가하고 있습니다. 노년층은 호르몬 불균형 및 관련 질환에 걸리기 쉽기 때문에 고령화도 이러한 성장에 기여하고 있습니다. 차세대 염기서열 분석 및 첨단 면역 측정법과 같은 진단 기술의 발전으로 내분비 검사가 더욱 정확하고 효율적이며 광범위하게 활용될 수 있게 됨에 따라 시장 확대가 더욱 가속화되고 있습니다. 예방적 헬스케어에 대한 관심이 높아진 것도 중요한 요인입니다. 호르몬 불균형을 조기에 발견하고 관리하는 것은 만성 질환의 발병을 예방하고 장기적인 건강 결과를 개선하는 데 매우 중요하기 때문입니다. 또한, 내분비 검사와 디지털 건강 플랫폼 및 원격 의료의 통합은 내분비 검사에 대한 접근성을 높이고 원격 모니터링 및 상담을 가능하게 하여, 특히 의료 서비스가 부족한 지역 및 지방의 환자들에게 도움이 될 수 있습니다. 또한, 내분비 검사와 유전자 및 생활습관 데이터를 결합하여 맞춤형 치료를 위한 맞춤의료의 발전은 내분비 검사가 맞춤의료의 도구로서 내분비 검사의 매력을 더욱 높여주고 있습니다. 이러한 추세는 내분비 검사가 질병 예방, 관리 및 맞춤 치료 전략의 핵심 요소로 자리 잡으면서 현대 의료에서 내분비 검사가 점점 더 중요해지고 있음을 보여줍니다.
조사 대상 기업 사례(총 31개 주목)
Agilent Technologies, Inc.
Apollo Diagnostics
Bio-Rad Laboratories, Inc.
Dartmouth-Hitchcock
DiaSorin SpA
F. Hoffmann-La Roche AG
HCA Healthcare UK
Holston Medical Group
Laboratory Corporation of America Holdings
Quest Diagnostics, Inc.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Endocrine Testing Market to Reach US$16.9 Billion by 2030
The global market for Endocrine Testing estimated at US$12.0 Billion in the year 2023, is expected to reach US$16.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Tandem Mass Spectrometry Technology, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 7.7% CAGR
The Endocrine Testing market in the U.S. is estimated at US$3.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
Global Endocrine Testing Market - Key Trends and Drivers Summarized
How Is Endocrine Testing Revolutionizing Healthcare and Disease Management?
Endocrine testing is revolutionizing healthcare and disease management by providing critical insights into the functioning of the body’s hormonal system, which plays a vital role in regulating metabolism, growth, reproduction, and overall well-being. This type of testing involves analyzing blood, urine, or saliva samples to measure hormone levels, which can help diagnose, monitor, and manage various endocrine disorders, such as diabetes, thyroid diseases, adrenal insufficiencies, and reproductive health issues. The accurate detection and monitoring of hormone imbalances are essential for effective treatment, as even small deviations from normal levels can significantly impact a person’s health. With advancements in testing technologies, endocrine testing has become more precise, accessible, and comprehensive, allowing healthcare providers to diagnose conditions earlier, tailor treatments more effectively, and monitor progress with greater accuracy. As the understanding of the endocrine system deepens and its link to chronic diseases like obesity, cardiovascular diseases, and osteoporosis becomes clearer, endocrine testing is increasingly seen as a cornerstone of preventive and personalized medicine.
What Innovations Are Enhancing the Functionality of Endocrine Testing?
Innovations in endocrine testing are enhancing its functionality through advancements in diagnostic technologies, automation, and personalized medicine. One of the most significant developments is the introduction of highly sensitive and specific assays, such as immunoassays and mass spectrometry, which allow for the accurate quantification of even minute hormone levels in the body. These advanced assays reduce the likelihood of false positives and negatives, providing more reliable diagnostic information. Automation in endocrine testing labs is another key innovation, enabling high-throughput processing of samples with minimal human intervention. This not only speeds up the testing process but also reduces the potential for human error, ensuring consistent and accurate results. Additionally, the integration of endocrine testing with personalized medicine approaches is transforming the way hormone-related conditions are managed. By combining hormone level data with genetic, lifestyle, and environmental factors, healthcare providers can create tailored treatment plans that address the unique needs of each patient, improving outcomes and reducing the risk of complications. Furthermore, the development of at-home testing kits for certain hormones, such as cortisol or thyroid-stimulating hormone (TSH), is making endocrine testing more accessible to the general public, allowing individuals to monitor their hormone levels conveniently and frequently. These innovations are making endocrine testing more precise, efficient, and patient-centered, driving improvements in the diagnosis and management of endocrine disorders.
How Does Endocrine Testing Impact Disease Management and Patient Outcomes?
Endocrine testing has a profound impact on disease management and patient outcomes by enabling early diagnosis, targeted treatment, and ongoing monitoring of hormone-related conditions. Early detection of endocrine disorders, such as hyperthyroidism, diabetes, or adrenal insufficiency, allows for timely intervention, which can prevent the progression of the disease and reduce the risk of severe complications. For example, identifying thyroid dysfunction early through endocrine testing can prevent complications like heart disease or mental health issues that may arise from untreated thyroid disorders. In managing chronic conditions like diabetes, regular endocrine testing is essential for monitoring blood glucose levels and adjusting treatment plans as needed, helping to maintain optimal blood sugar control and prevent complications such as neuropathy or cardiovascular disease. The ability to measure and monitor hormone levels accurately also allows healthcare providers to fine-tune treatments, ensuring that medications are dosed correctly and that therapies are tailored to the individual’s hormonal profile. This personalized approach not only improves the effectiveness of treatment but also enhances patient compliance and satisfaction, as treatments are more likely to align with the patient’s specific needs and lifestyle. By providing critical information that guides the management of endocrine disorders, endocrine testing plays a vital role in improving patient outcomes and quality of life.
What Trends Are Driving Growth in the Endocrine Testing Market?
Several trends are driving growth in the endocrine testing market, including the rising prevalence of endocrine disorders, advancements in diagnostic technologies, and the increasing focus on preventive healthcare. The global rise in conditions such as diabetes, thyroid disorders, and metabolic syndromes is fueling demand for accurate and comprehensive endocrine testing, as these conditions require ongoing monitoring and management. The aging population is also contributing to this growth, as older adults are more susceptible to hormone imbalances and related diseases. Advancements in diagnostic technologies, such as next-generation sequencing and advanced immunoassays, are making endocrine testing more accurate, efficient, and widely available, further driving market expansion. The growing emphasis on preventive healthcare is another key factor, as early detection and management of hormone imbalances are critical in preventing the onset of chronic diseases and improving long-term health outcomes. Additionally, the integration of endocrine testing with digital health platforms and telemedicine is expanding access to these tests, allowing for remote monitoring and consultation, which is particularly beneficial for patients in underserved or rural areas. The development of personalized medicine approaches, which combine endocrine testing with genetic and lifestyle data to tailor treatments, is also enhancing the appeal of endocrine testing as a tool for individualized care. These trends highlight the increasing importance of endocrine testing in modern healthcare, as it becomes a central component of disease prevention, management, and personalized treatment strategies.
Select Competitors (Total 31 Featured) -
Agilent Technologies, Inc.
Apollo Diagnostics
Bio-Rad Laboratories, Inc.
Dartmouth-Hitchcock
DiaSorin SpA
F. Hoffmann-La Roche AG
HCA Healthcare UK
Holston Medical Group
Laboratory Corporation of America Holdings
Quest Diagnostics, Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Endocrine Testing - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Global Prevalence of Endocrine Disorders Driving Demand for Testing
Technological Advancements in Diagnostic Tests Enhancing Accuracy and Speed
Integration of Telehealth and Remote Testing Options Expanding Accessibility
Impact of Lifestyle Diseases on the Growing Need for Endocrine Testing
Developments in Biomarker Discovery and Its Application in Endocrine Disorders
Future Outlook: AI Integration in Diagnostic Workflows for Endocrine Disorders
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Insulin Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Estradiol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Clinical Chemistry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Monoclonal & Polyclonal Antibody Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for Sensors Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 34: World Endocrine Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 35: World Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
JAPAN
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 50: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Japan 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
CHINA
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 56: China Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: China Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: China 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 59: China Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: China Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: China 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
EUROPE
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 62: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 65: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Europe 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 71: France Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: France Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: France 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 74: France Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: France Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: France 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
GERMANY
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 77: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Germany Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Germany 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 80: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Germany Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Germany 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
ITALY
TABLE 83: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Italy Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Italy 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 86: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Italy Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Italy 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
UNITED KINGDOM
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 89: UK Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: UK Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: UK 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 92: UK Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: UK Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: UK 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
SPAIN
TABLE 95: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Spain Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Spain 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 98: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Spain Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Spain 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
RUSSIA
TABLE 101: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Russia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Russia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 104: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Russia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Russia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Rest of Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Rest of Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 120: Asia-Pacific Historic Review for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Asia-Pacific 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 122: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Australia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Australia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 125: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Australia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Australia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
INDIA
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 128: India Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: India Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: India 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 131: India Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: India Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: India 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 134: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: South Korea Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: South Korea 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 137: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: South Korea Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: South Korea 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
LATIN AMERICA
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 146: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 149: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
TABLE 152: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 153: Latin America Historic Review for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Latin America 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
ARGENTINA
TABLE 155: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Argentina Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Argentina 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 158: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Argentina Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Argentina 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
BRAZIL
TABLE 161: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Brazil Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Brazil 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 164: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Brazil Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Brazil 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
MEXICO
TABLE 167: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Mexico Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Mexico 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 170: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Mexico Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Mexico 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Rest of Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Rest of Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Rest of Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Rest of Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
MIDDLE EAST
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 179: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 182: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
TABLE 185: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 186: Middle East Historic Review for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Middle East 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
IRAN
TABLE 188: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Iran Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Iran 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 191: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Iran Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Iran 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
ISRAEL
TABLE 194: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Israel Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Israel 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 197: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Israel Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Israel 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Saudi Arabia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Saudi Arabia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Saudi Arabia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Saudi Arabia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 206: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: UAE Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: UAE 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 209: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: UAE Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: UAE 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Rest of Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Rest of Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Rest of Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Rest of Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
AFRICA
Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 218: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Africa Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Africa 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
TABLE 221: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 222: Africa Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 223: Africa 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030